Search

Your search keyword '"Nisard, Andrée"' showing total 2 results
Start Over Author "Nisard, Andrée" Topic inflammatory bowel diseases
2 results on '"Nisard, Andrée"'

1. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study.

Author

Coelho J, Beaugerie L, Colombel JF, Hébuterne X, Lerebours E, Lémann M, Baumer P, Cosnes J, Bourreille A, Gendre JP, Seksik P, Blain A, Metman EH, Nisard A, Cadiot G, Veyrac M, Coffin B, Dray X, Carrat F, and Marteau P

Subjects
Abnormalities, Drug-Induced epidemiology, Abnormalities, Drug-Induced etiology, Adult, Birth Weight, Cohort Studies, Female, France epidemiology, Humans, Immunosuppressive Agents therapeutic use, Infant, Newborn, Inflammatory Bowel Diseases epidemiology, Maternal-Fetal Exchange, Mercaptopurine therapeutic use, Pregnancy, Pregnancy Complications epidemiology, Prenatal Exposure Delayed Effects, Treatment Outcome, Young Adult, Immunosuppressive Agents adverse effects, Inflammatory Bowel Diseases drug therapy, Mercaptopurine adverse effects, Pregnancy Complications drug therapy, Pregnancy Outcome
Abstract

Background and Aims: Few studies have been conducted addressing the safety of thiopurine treatment in pregnant women with inflammatory bowel disease (IBD). The aim of this study was to evaluate the pregnancy outcome of women with IBD who have been exposed to thiopurines., Methods: 215 pregnancies in 204 women were registered and documented in the CESAME cohort between May 2004 and October 2007. Physicians documented the following information from the women: last menstrual date, delivery term, details of pregnancy outcome, prematurity, birth weight and height, congenital abnormalities, medication history during each trimester, smoking history and alcohol ingestion. Data were compared between three groups: women exposed to thiopurines (group A), women receiving a drug other than thiopurines (group B) and women not receiving any medication (group C)., Results: Mean age at pregnancy was 28.3 years. 75.7% of the women had Crohn's disease and 21.8% had ulcerative colitis, with a mean disease duration of 6.8 years at inclusion. Of the 215 pregnancies, there were 138 births (142 newborns), and the mean birth weight was 3135 g. There were 86 pregnancies in group A, 84 in group B and 45 in group C. Interrupted pregnancies occurred in 36% of patients enrolled in group A, 33% of patients enrolled in group B, and 40% of patients enrolled in group C; congenital abnormalities arose in 3.6% of group A cases and 7.1% of group B cases. No significant differences were found between the three groups in overall pregnancy outcome., Conclusions: The results obtained from this cohort indicate that thiopurine use during pregnancy is not associated with increased risks, including congenital abnormalities.

Published
2011
Full Text
View/download PDF

2. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study

Author

Coelho, Jessica, Beaugerie, Laurent, Colombel, Jean Frédéric, Hébuterne, Xavier, Lerebours, Eric, Lémann, Marc, Baumer, Philippe, Cosnes, Jacques, Bourreille, Arnaud, Gendre, Jean Pierre, Seksik, Philippe, Blain, Antoine, Metman, Etienne H, Nisard, Andrée, Cadiot, Guillaume, Veyrac, Michel, Coffin, Benoît, Dray, Xavier, Carrat, Fabrice, Marteau, Philippe, Renseigné, Non, Institut de Génomique Fonctionnelle (IGF), Université de Montpellier (UM)-Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Centre National de la Recherche Scientifique (CNRS), Service de Gastroentérologie et nutrition [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Université Pierre et Marie Curie - Paris 6 (UPMC), Centre d'Investigation Clinique Lille, PRES Université Lille Nord de France-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hépato-Gastroentérologie, Centre Hospitalier Universitaire de Nice (CHU Nice), Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Appareil Digestif Environnement Nutrition (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), Service de gastro-entérologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Gastro-Entérologie et Nutrition, Neuropathies du système nerveux entérique et pathologies digestives, implication des cellules gliales entériques, Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des Maladies de l'Appareil Digestif, Université de Nantes (UN), Université de Reims Champagne-Ardenne (URCA), Fédération Médico-Chirurgicale des Maladies de l'Appareil Digestif, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-CHU Saint-Eloi, Département de Gastroentérologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Dauphine-PSL, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Hôpital Louis Mourier - AP-HP [Colombes], Epidémiologie des maladies infectieuses et modélisation (ESIM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Université Montpellier 1 (UM1)-Université Montpellier 2 - Sciences et Techniques (UM2)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Saint Eloi (CHRU Montpellier), and Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)

Subjects
Adult, medicine.medical_specialty, Medication history, Birth weight, Inflammatory bowel disease, Cohort Studies, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Pregnancy, medicine, Birth Weight, Humans, Maternal-Fetal Exchange, Crohn's disease, Thiopurine methyltransferase, biology, Mercaptopurine, Obstetrics, business.industry, [CHIM.ORGA]Chemical Sciences/Organic chemistry, Infant, Newborn, Pregnancy Outcome, Gastroenterology, Abnormalities, Drug-Induced, Inflammatory Bowel Diseases, medicine.disease, 3. Good health, Surgery, Pregnancy Complications, Treatment Outcome, Prenatal Exposure Delayed Effects, 030220 oncology & carcinogenesis, Cohort, biology.protein, Female, 030211 gastroenterology & hepatology, France, business, Immunosuppressive Agents, Cohort study
Abstract

International audience; BACKGROUND AND AIMS: Few studies have been conducted addressing the safety of thiopurine treatment in pregnant women with inflammatory bowel disease (IBD). The aim of this study was to evaluate the pregnancy outcome of women with IBD who have been exposed to thiopurines. METHODS: 215 pregnancies in 204 women were registered and documented in the CESAME cohort between May 2004 and October 2007. Physicians documented the following information from the women: last menstrual date, delivery term, details of pregnancy outcome, prematurity, birth weight and height, congenital abnormalities, medication history during each trimester, smoking history and alcohol ingestion. Data were compared between three groups: women exposed to thiopurines (group A), women receiving a drug other than thiopurines (group B) and women not receiving any medication (group C). RESULTS: Mean age at pregnancy was 28.3 years. 75.7% of the women had Crohn's disease and 21.8% had ulcerative colitis, with a mean disease duration of 6.8 years at inclusion. Of the 215 pregnancies, there were 138 births (142 newborns), and the mean birth weight was 3135 g. There were 86 pregnancies in group A, 84 in group B and 45 in group C. Interrupted pregnancies occurred in 36% of patients enrolled in group A, 33% of patients enrolled in group B, and 40% of patients enrolled in group C; congenital abnormalities arose in 3.6% of group A cases and 7.1% of group B cases. No significant differences were found between the three groups in overall pregnancy outcome. CONCLUSIONS: The results obtained from this cohort indicate that thiopurine use during pregnancy is not associated with increased risks, including congenital abnormalities.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results